OncoX and ABVC BioPharma Strengthen Collaboration to Advance Oncology Treatments
OncoX BioPharma's deepened alliance with ABVC BioPharma signifies a strategic move to enhance its oncology pipeline, leveraging ABVC's IND-stage programs to develop innovative cancer therapies.
The collaboration between OncoX BioPharma, Inc. and ABVC BioPharma, Inc. has taken a significant step forward, marking a pivotal moment in the development of next-generation cancer treatments. This partnership, rooted in the licensing of four IND-stage drug assets from ABVC to OncoX, underscores a shared commitment to innovation in oncology. OncoX, under the leadership of CEO Yen Wen Pin, is leveraging its expertise in natural product innovation to build a robust pipeline of immunotherapy-driven treatments, supported by ABVC's clinical-stage portfolio.
Mr. Yen Wen Pin emphasized the long-term vision of OncoX, stating, 'We are building OncoX with a long-term vision to deliver real value to patients and investors.' This vision is being realized through the strategic advancement of licensed INDs from ABVC, which are expected to anchor OncoX's strategy in the cancer therapeutics space. The recent fulfillment of an additional milestone payment by OncoX highlights the company's operational discipline and commitment to progressing these oncology programs.
ABVC's Chief Executive Officer, Dr. Uttam Patil, reflected on the partnership's success, noting, 'OncoX’s consistent execution has translated into steady licensing revenue for ABVC and increasing momentum around these oncology programs.' To date, ABVC and its subsidiaries have recorded a cumulative licensing income of $1.396 million from OncoX and other strategic partners, including AiBtl BioPharma and ForSeeCon Eye Corporation.
OncoX's roadmap is characterized by a blend of innovation and pragmatism, with a focus on developing not only promising drug candidates but also a revenue-generating model grounded in credibility and commercial viability. The company's expansion into cancer-supportive care and preventative health, through proprietary natural ingredients and the acquisition of the Lycogen® extraction platform, further illustrates its strategic diversification. According to Allied Market Research, the global market for these cross-sector applications is projected to reach $187 million by 2030. For more information on the lycopene market, visit https://www.prnewswire.com/news-releases/lycopene-market-to-reach-187-3-million-globally-by-2030-at-5-2-cagr-allied-market-research-301371075.html.
As OncoX prepares for future clinical milestones and pursues international partnerships, the collaboration with ABVC stands as a testament to the potential of strategic biotech alliances to drive innovation and deliver value to patients worldwide.